Newborn Screening Market Synopsis:

Newborn Screening Market Size Was Valued at USD 848.8 Million in 2023 and is Projected to Reach USD 1635.6 Million by 2032, Growing at a CAGR of 7.56% From 2024-2032.

The newborn screening market is expanding rapidly as early detection of genetic, metabolic, and developmental disorders becomes a global healthcare priority. Newborn screening involves testing infants shortly after birth to identify potentially serious health conditions that can benefit from early intervention. The increasing awareness among parents and healthcare providers about the importance of early diagnosis, coupled with the rising prevalence of congenital disorders, is driving demand for advanced screening solutions. Government initiatives in many regions further support newborn screening programs by mandating testing for a range of treatable conditions, thereby enhancing market growth.

Technological advancements in screening methodologies have transformed the newborn screening market, enabling the detection of a broader spectrum of conditions with higher accuracy and efficiency. Mass spectrometry and DNA-based tests, for instance, are gaining popularity as they allow for rapid and precise identification of disorders. These technologies have helped expand the range of detectable conditions, from metabolic and endocrine disorders to hearing impairments and critical congenital heart defects. In addition, innovations in sample collection methods, such as dried blood spot (DBS) testing, have improved the convenience and accuracy of these screenings.

The newborn screening market is also driven by increasing investments in research and development from both government bodies and private companies. North America and Europe currently dominate the market due to strong healthcare infrastructure and widespread adoption of screening programs. However, emerging markets in Asia-Pacific and Latin America show significant growth potential as awareness and healthcare spending in these regions rise. With the ongoing focus on early diagnosis and preventive healthcare, the newborn screening market is poised for continued growth, as it plays a critical role in improving long-term health outcomes for infants globally.

Newborn Screening Market Trend Analysis:

Expansion of Screening Panels to Include Genetic and Rare Disorders

  • A major trend in the newborn screening market is the expansion of screening panels to detect a wider array of genetic and rare disorders. Advances in genetic testing technology now allow healthcare providers to screen newborns for complex conditions such as spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID), among others. This broader scope improves early diagnosis and treatment options for rare conditions, significantly impacting the quality of life for affected infants and supporting market growth.

Rise of Digital Health Solutions and Data Integration

  • The adoption of digital health solutions and data integration platforms in newborn screening programs is another significant trend. These technologies streamline the management and tracking of screening results, enabling healthcare providers to deliver timely follow-up care. Additionally, data integration allows for better collaboration among healthcare facilities, labs, and public health organizations, improving the efficiency and accuracy of screening programs. This trend is particularly prominent in developed regions but is increasingly spreading to emerging markets as digital infrastructure expands.

Newborn Screening Market Segment Analysis:

Newborn Screening Market is Segmented on the basis of Test Type, Product Type, Technology, Disease Type, End User, and Region.

By Test Type, Dried Blood Spot Test segment is expected to dominate the market during the forecast period

  • The newborn screening market offers various test types, including the dried blood spot (DBS) test, hearing screen test, and critical congenital heart diseases (CCHD) test, each playing a vital role in early infant health assessment. The dried blood spot test is widely used to screen for metabolic, genetic, and endocrine disorders by analyzing a small blood sample from a newborn's heel. Hearing screening tests are essential for identifying congenital hearing loss, allowing for timely intervention that can aid in language development. Meanwhile, the CCHD test uses pulse oximetry to detect heart defects that might not be apparent at birth, facilitating immediate treatment if necessary. Together, these screening methods ensure a comprehensive assessment of newborn health, supporting early detection and improved health outcomes.

By End User, Hospital segment expected to held the largest share

  • In the newborn screening market, key end users include hospitals, pediatric clinics, and specialized clinics, each playing a vital role in ensuring early detection and intervention for various congenital and metabolic disorders. Hospitals are often the primary setting for newborn screening, given their access to advanced equipment and specialized staff needed for initial testing shortly after birth. Pediatric clinics follow up on screening results, providing ongoing monitoring and care to manage any detected conditions, while smaller clinics may serve as additional screening sites in certain regions, expanding accessibility to screening services. Together, these end users form a comprehensive network that supports early diagnosis, timely intervention, and effective management of newborn health conditions, enhancing overall care quality.

Newborn Screening Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

  • North America is expected to dominate the newborn screening market over the forecast period, driven by strong healthcare infrastructure, high awareness of early diagnosis benefits, and supportive government policies. The United States, in particular, has well-established newborn screening programs that mandate testing for various congenital disorders, supported by federal and state-level funding. Additionally, advancements in screening technologies, such as genetic testing and mass spectrometry, are widely adopted in this region, contributing to the market’s growth. Increased investments in research and development, along with a high rate of adoption among hospitals and healthcare facilities, further strengthen North America’s leading position in the newborn screening market.

Active Key Players in the Newborn Screening Market:

  • PerkinElmer Inc., (U.S)
  • Demant A/S (Denmark)
  • Natus Medical Incorporated (U.S)
  • Bio-Rad Laboratories (U.S)
  • Luminex Corporation (US)
  • F. Hoffmann-La Roche Ltd., (Switzerland)
  • Thermo Fisher Scientific Inc., (U.S)
  • Bruker (US),  Danaher (US)
  • Medtronic (Ireland)
  • Chromsystems Instruments & Chemicals GmbH (Germany)
  • Trivitron Healthcare (India)
  • Baebies Inc., (U.S)
  • RECIPE Chemicals + Instruments GmbH (Germany)
  • Other Active Players

                                                               Global Newborn Screening Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 848.8 Billion

Forecast Period 2024-32 CAGR:

 7.56%

Market Size in 2032:

USD 1635.6 Billion

Segments Covered:

By Test Type
  • Dried Blood Spot Test
  • Hearing Screen Test
  • Critical Congenital Heart Diseases (CCHD) Test

By Product Type
  • Instruments
  • Reagents
  • Assay Kits

By Technology
  • Tandem Mass Spectrometry
  • Hearing Screen Technology
  • Pulse Oximetry Screening Technology
  • Immunoassays and Enzymatic Assays
  • Electrophoresis
  • DNA-Based Assays

By Disease Type
  • Critical Congenital Heart Diseases
  • Newborn Hearing Loss
  • Sickle Cell Disease
  • Phenylketonuria (PKU)
  • Cystic Fibrosis (CF)
  • Maple Syrup Urine Disease
  • Others

By End User
  • Hospital,
  • Paediatric Clinics,
  • Clinics

By Region
  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:
  • Newborn screening is rising due to genetic diseases and awareness of early detection benefits.

Key Market Restraints:
  • The high cost of modern screening technologies and restricted accessibility in low-income locations can slow market expansion.

Key Opportunities:
  • Genetic testing and digital health solutions offer worldwide newborn screening program expansion prospects.

Companies Covered in the report:
  • PerkinElmer Inc., (U.S), Demant A/S (Denmark), Natus Medical Incorporated (U.S), Bio-Rad Laboratories (U.S), Luminex Corporation (US),  F. Hoffmann-La Roche Ltd., (Switzerland), Thermo Fisher Scientific Inc., (U.S), Bruker (US),  Danaher (US), Medtronic (Ireland), Chromsystems Instruments & Chemicals GmbH (Germany), Trivitron Healthcare (India), Baebies Inc., (U.S), and RECIPE Chemicals + Instruments GmbH (Germany), and Other Active Players.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Newborn Screening Market by Test Type
 4.1 Newborn Screening Market Snapshot and Growth Engine
 4.2 Newborn Screening Market Overview
 4.3 Dried Blood Spot Test
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Dried Blood Spot Test: Geographic Segmentation Analysis
 4.4 Hearing Screen Test
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Hearing Screen Test: Geographic Segmentation Analysis
 4.5 Critical Congenital Heart Diseases (CCHD) Test
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Critical Congenital Heart Diseases (CCHD) Test: Geographic Segmentation Analysis

Chapter 5: Newborn Screening Market by Product Type
 5.1 Newborn Screening Market Snapshot and Growth Engine
 5.2 Newborn Screening Market Overview
 5.3 Instruments
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Instruments: Geographic Segmentation Analysis
 5.4 Reagents
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Reagents: Geographic Segmentation Analysis
 5.5 Assay Kits
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Assay Kits: Geographic Segmentation Analysis

Chapter 6: Newborn Screening Market by Technology
 6.1 Newborn Screening Market Snapshot and Growth Engine
 6.2 Newborn Screening Market Overview
 6.3 Tandem Mass Spectrometry
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Tandem Mass Spectrometry: Geographic Segmentation Analysis
 6.4 Hearing Screen Technology
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Hearing Screen Technology: Geographic Segmentation Analysis
 6.5 Pulse Oximetry Screening Technology
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Pulse Oximetry Screening Technology: Geographic Segmentation Analysis
 6.6 Immunoassays and Enzymatic Assays
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Immunoassays and Enzymatic Assays: Geographic Segmentation Analysis
 6.7 Electrophoresis
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Electrophoresis: Geographic Segmentation Analysis
 6.8 DNA-Based Assays
  6.8.1 Introduction and Market Overview
  6.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.8.3 Key Market Trends, Growth Factors and Opportunities
  6.8.4 DNA-Based Assays: Geographic Segmentation Analysis

Chapter 7: Newborn Screening Market by Disease Type
 7.1 Newborn Screening Market Snapshot and Growth Engine
 7.2 Newborn Screening Market Overview
 7.3 Critical Congenital Heart Diseases
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Critical Congenital Heart Diseases: Geographic Segmentation Analysis
 7.4 Newborn Hearing Loss
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Newborn Hearing Loss: Geographic Segmentation Analysis
 7.5 Sickle Cell Disease
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Sickle Cell Disease: Geographic Segmentation Analysis
 7.6 Phenylketonuria (PKU)
  7.6.1 Introduction and Market Overview
  7.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.6.3 Key Market Trends, Growth Factors and Opportunities
  7.6.4 Phenylketonuria (PKU): Geographic Segmentation Analysis
 7.7 Cystic Fibrosis (CF)
  7.7.1 Introduction and Market Overview
  7.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.7.3 Key Market Trends, Growth Factors and Opportunities
  7.7.4 Cystic Fibrosis (CF): Geographic Segmentation Analysis
 7.8 Maple Syrup Urine Disease
  7.8.1 Introduction and Market Overview
  7.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.8.3 Key Market Trends, Growth Factors and Opportunities
  7.8.4 Maple Syrup Urine Disease: Geographic Segmentation Analysis
 7.9 Others
  7.9.1 Introduction and Market Overview
  7.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.9.3 Key Market Trends, Growth Factors and Opportunities
  7.9.4 Others: Geographic Segmentation Analysis

Chapter 8: Newborn Screening Market by End User
 8.1 Newborn Screening Market Snapshot and Growth Engine
 8.2 Newborn Screening Market Overview
 8.3 Hospital
  8.3.1 Introduction and Market Overview
  8.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  8.3.3 Key Market Trends, Growth Factors and Opportunities
  8.3.4 Hospital: Geographic Segmentation Analysis
 8.4 Paediatric Clinics
  8.4.1 Introduction and Market Overview
  8.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  8.4.3 Key Market Trends, Growth Factors and Opportunities
  8.4.4 Paediatric Clinics: Geographic Segmentation Analysis
 8.5 Clinics
  8.5.1 Introduction and Market Overview
  8.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  8.5.3 Key Market Trends, Growth Factors and Opportunities
  8.5.4 Clinics: Geographic Segmentation Analysis

Chapter 9: Company Profiles and Competitive Analysis
 9.1 Competitive Landscape
  9.1.1 Competitive Benchmarking
  9.1.2 Newborn Screening Market Share by Manufacturer (2023)
  9.1.3 Industry BCG Matrix
  9.1.4 Heat Map Analysis
  9.1.5 Mergers and Acquisitions  
 9.2 PERKINELMER INC.
  9.2.1 Company Overview
  9.2.2 Key Executives
  9.2.3 Company Snapshot
  9.2.4 Role of the Company in the Market
  9.2.5 Sustainability and Social Responsibility
  9.2.6 Operating Business Segments
  9.2.7 Product Portfolio
  9.2.8 Business Performance
  9.2.9 Key Strategic Moves and Recent Developments
  9.2.10 SWOT Analysis
 9.3 (U.S)
 9.4 DEMANT A/S (DENMARK)
 9.5 NATUS MEDICAL INCORPORATED (U.S)
 9.6 BIO-RAD LABORATORIES (U.S)
 9.7 LUMINEX CORPORATION (US)
 9.8 F. HOFFMANN-LA ROCHE LTD.
 9.9 (SWITZERLAND)
 9.10 THERMO FISHER SCIENTIFIC INC.
 9.11 (U.S)
 9.12 BRUKER (US)
 9.13 DANAHER (US)
 9.14 MEDTRONIC (IRELAND)
 9.15 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH (GERMANY)
 9.16 TRIVITRON HEALTHCARE (INDIA)
 9.17 BAEBIES INC.
 9.18 (U.S)
 9.19 RECIPE CHEMICALS + INSTRUMENTS GMBH (GERMANY)
 9.20 OTHER ACTIVE PLAYERS
 9.21 OTHER ACTIVE PLAYERS

Chapter 10: Global Newborn Screening Market By Region
 10.1 Overview
 10.2. North America Newborn Screening Market
  10.2.1 Key Market Trends, Growth Factors and Opportunities
  10.2.2 Top Key Companies
  10.2.3 Historic and Forecasted Market Size by Segments
  10.2.4 Historic and Forecasted Market Size By Test Type
  10.2.4.1 Dried Blood Spot Test
  10.2.4.2 Hearing Screen Test
  10.2.4.3 Critical Congenital Heart Diseases (CCHD) Test
  10.2.5 Historic and Forecasted Market Size By Product Type
  10.2.5.1 Instruments
  10.2.5.2 Reagents
  10.2.5.3 Assay Kits
  10.2.6 Historic and Forecasted Market Size By Technology
  10.2.6.1 Tandem Mass Spectrometry
  10.2.6.2 Hearing Screen Technology
  10.2.6.3 Pulse Oximetry Screening Technology
  10.2.6.4 Immunoassays and Enzymatic Assays
  10.2.6.5 Electrophoresis
  10.2.6.6 DNA-Based Assays
  10.2.7 Historic and Forecasted Market Size By Disease Type
  10.2.7.1 Critical Congenital Heart Diseases
  10.2.7.2 Newborn Hearing Loss
  10.2.7.3 Sickle Cell Disease
  10.2.7.4 Phenylketonuria (PKU)
  10.2.7.5 Cystic Fibrosis (CF)
  10.2.7.6 Maple Syrup Urine Disease
  10.2.7.7 Others
  10.2.8 Historic and Forecasted Market Size By End User
  10.2.8.1 Hospital
  10.2.8.2 Paediatric Clinics
  10.2.8.3 Clinics
  10.2.9 Historic and Forecast Market Size by Country
  10.2.9.1 US
  10.2.9.2 Canada
  10.2.9.3 Mexico
 10.3. Eastern Europe Newborn Screening Market
  10.3.1 Key Market Trends, Growth Factors and Opportunities
  10.3.2 Top Key Companies
  10.3.3 Historic and Forecasted Market Size by Segments
  10.3.4 Historic and Forecasted Market Size By Test Type
  10.3.4.1 Dried Blood Spot Test
  10.3.4.2 Hearing Screen Test
  10.3.4.3 Critical Congenital Heart Diseases (CCHD) Test
  10.3.5 Historic and Forecasted Market Size By Product Type
  10.3.5.1 Instruments
  10.3.5.2 Reagents
  10.3.5.3 Assay Kits
  10.3.6 Historic and Forecasted Market Size By Technology
  10.3.6.1 Tandem Mass Spectrometry
  10.3.6.2 Hearing Screen Technology
  10.3.6.3 Pulse Oximetry Screening Technology
  10.3.6.4 Immunoassays and Enzymatic Assays
  10.3.6.5 Electrophoresis
  10.3.6.6 DNA-Based Assays
  10.3.7 Historic and Forecasted Market Size By Disease Type
  10.3.7.1 Critical Congenital Heart Diseases
  10.3.7.2 Newborn Hearing Loss
  10.3.7.3 Sickle Cell Disease
  10.3.7.4 Phenylketonuria (PKU)
  10.3.7.5 Cystic Fibrosis (CF)
  10.3.7.6 Maple Syrup Urine Disease
  10.3.7.7 Others
  10.3.8 Historic and Forecasted Market Size By End User
  10.3.8.1 Hospital
  10.3.8.2 Paediatric Clinics
  10.3.8.3 Clinics
  10.3.9 Historic and Forecast Market Size by Country
  10.3.9.1 Russia
  10.3.9.2 Bulgaria
  10.3.9.3 The Czech Republic
  10.3.9.4 Hungary
  10.3.9.5 Poland
  10.3.9.6 Romania
  10.3.9.7 Rest of Eastern Europe
 10.4. Western Europe Newborn Screening Market
  10.4.1 Key Market Trends, Growth Factors and Opportunities
  10.4.2 Top Key Companies
  10.4.3 Historic and Forecasted Market Size by Segments
  10.4.4 Historic and Forecasted Market Size By Test Type
  10.4.4.1 Dried Blood Spot Test
  10.4.4.2 Hearing Screen Test
  10.4.4.3 Critical Congenital Heart Diseases (CCHD) Test
  10.4.5 Historic and Forecasted Market Size By Product Type
  10.4.5.1 Instruments
  10.4.5.2 Reagents
  10.4.5.3 Assay Kits
  10.4.6 Historic and Forecasted Market Size By Technology
  10.4.6.1 Tandem Mass Spectrometry
  10.4.6.2 Hearing Screen Technology
  10.4.6.3 Pulse Oximetry Screening Technology
  10.4.6.4 Immunoassays and Enzymatic Assays
  10.4.6.5 Electrophoresis
  10.4.6.6 DNA-Based Assays
  10.4.7 Historic and Forecasted Market Size By Disease Type
  10.4.7.1 Critical Congenital Heart Diseases
  10.4.7.2 Newborn Hearing Loss
  10.4.7.3 Sickle Cell Disease
  10.4.7.4 Phenylketonuria (PKU)
  10.4.7.5 Cystic Fibrosis (CF)
  10.4.7.6 Maple Syrup Urine Disease
  10.4.7.7 Others
  10.4.8 Historic and Forecasted Market Size By End User
  10.4.8.1 Hospital
  10.4.8.2 Paediatric Clinics
  10.4.8.3 Clinics
  10.4.9 Historic and Forecast Market Size by Country
  10.4.9.1 Germany
  10.4.9.2 UK
  10.4.9.3 France
  10.4.9.4 The Netherlands
  10.4.9.5 Italy
  10.4.9.6 Spain
  10.4.9.7 Rest of Western Europe
 10.5. Asia Pacific Newborn Screening Market
  10.5.1 Key Market Trends, Growth Factors and Opportunities
  10.5.2 Top Key Companies
  10.5.3 Historic and Forecasted Market Size by Segments
  10.5.4 Historic and Forecasted Market Size By Test Type
  10.5.4.1 Dried Blood Spot Test
  10.5.4.2 Hearing Screen Test
  10.5.4.3 Critical Congenital Heart Diseases (CCHD) Test
  10.5.5 Historic and Forecasted Market Size By Product Type
  10.5.5.1 Instruments
  10.5.5.2 Reagents
  10.5.5.3 Assay Kits
  10.5.6 Historic and Forecasted Market Size By Technology
  10.5.6.1 Tandem Mass Spectrometry
  10.5.6.2 Hearing Screen Technology
  10.5.6.3 Pulse Oximetry Screening Technology
  10.5.6.4 Immunoassays and Enzymatic Assays
  10.5.6.5 Electrophoresis
  10.5.6.6 DNA-Based Assays
  10.5.7 Historic and Forecasted Market Size By Disease Type
  10.5.7.1 Critical Congenital Heart Diseases
  10.5.7.2 Newborn Hearing Loss
  10.5.7.3 Sickle Cell Disease
  10.5.7.4 Phenylketonuria (PKU)
  10.5.7.5 Cystic Fibrosis (CF)
  10.5.7.6 Maple Syrup Urine Disease
  10.5.7.7 Others
  10.5.8 Historic and Forecasted Market Size By End User
  10.5.8.1 Hospital
  10.5.8.2 Paediatric Clinics
  10.5.8.3 Clinics
  10.5.9 Historic and Forecast Market Size by Country
  10.5.9.1 China
  10.5.9.2 India
  10.5.9.3 Japan
  10.5.9.4 South Korea
  10.5.9.5 Malaysia
  10.5.9.6 Thailand
  10.5.9.7 Vietnam
  10.5.9.8 The Philippines
  10.5.9.9 Australia
  10.5.9.10 New Zealand
  10.5.9.11 Rest of APAC
 10.6. Middle East & Africa Newborn Screening Market
  10.6.1 Key Market Trends, Growth Factors and Opportunities
  10.6.2 Top Key Companies
  10.6.3 Historic and Forecasted Market Size by Segments
  10.6.4 Historic and Forecasted Market Size By Test Type
  10.6.4.1 Dried Blood Spot Test
  10.6.4.2 Hearing Screen Test
  10.6.4.3 Critical Congenital Heart Diseases (CCHD) Test
  10.6.5 Historic and Forecasted Market Size By Product Type
  10.6.5.1 Instruments
  10.6.5.2 Reagents
  10.6.5.3 Assay Kits
  10.6.6 Historic and Forecasted Market Size By Technology
  10.6.6.1 Tandem Mass Spectrometry
  10.6.6.2 Hearing Screen Technology
  10.6.6.3 Pulse Oximetry Screening Technology
  10.6.6.4 Immunoassays and Enzymatic Assays
  10.6.6.5 Electrophoresis
  10.6.6.6 DNA-Based Assays
  10.6.7 Historic and Forecasted Market Size By Disease Type
  10.6.7.1 Critical Congenital Heart Diseases
  10.6.7.2 Newborn Hearing Loss
  10.6.7.3 Sickle Cell Disease
  10.6.7.4 Phenylketonuria (PKU)
  10.6.7.5 Cystic Fibrosis (CF)
  10.6.7.6 Maple Syrup Urine Disease
  10.6.7.7 Others
  10.6.8 Historic and Forecasted Market Size By End User
  10.6.8.1 Hospital
  10.6.8.2 Paediatric Clinics
  10.6.8.3 Clinics
  10.6.9 Historic and Forecast Market Size by Country
  10.6.9.1 Turkiye
  10.6.9.2 Bahrain
  10.6.9.3 Kuwait
  10.6.9.4 Saudi Arabia
  10.6.9.5 Qatar
  10.6.9.6 UAE
  10.6.9.7 Israel
  10.6.9.8 South Africa
 10.7. South America Newborn Screening Market
  10.7.1 Key Market Trends, Growth Factors and Opportunities
  10.7.2 Top Key Companies
  10.7.3 Historic and Forecasted Market Size by Segments
  10.7.4 Historic and Forecasted Market Size By Test Type
  10.7.4.1 Dried Blood Spot Test
  10.7.4.2 Hearing Screen Test
  10.7.4.3 Critical Congenital Heart Diseases (CCHD) Test
  10.7.5 Historic and Forecasted Market Size By Product Type
  10.7.5.1 Instruments
  10.7.5.2 Reagents
  10.7.5.3 Assay Kits
  10.7.6 Historic and Forecasted Market Size By Technology
  10.7.6.1 Tandem Mass Spectrometry
  10.7.6.2 Hearing Screen Technology
  10.7.6.3 Pulse Oximetry Screening Technology
  10.7.6.4 Immunoassays and Enzymatic Assays
  10.7.6.5 Electrophoresis
  10.7.6.6 DNA-Based Assays
  10.7.7 Historic and Forecasted Market Size By Disease Type
  10.7.7.1 Critical Congenital Heart Diseases
  10.7.7.2 Newborn Hearing Loss
  10.7.7.3 Sickle Cell Disease
  10.7.7.4 Phenylketonuria (PKU)
  10.7.7.5 Cystic Fibrosis (CF)
  10.7.7.6 Maple Syrup Urine Disease
  10.7.7.7 Others
  10.7.8 Historic and Forecasted Market Size By End User
  10.7.8.1 Hospital
  10.7.8.2 Paediatric Clinics
  10.7.8.3 Clinics
  10.7.9 Historic and Forecast Market Size by Country
  10.7.9.1 Brazil
  10.7.9.2 Argentina
  10.7.9.3 Rest of SA

Chapter 11 Analyst Viewpoint and Conclusion
11.1 Recommendations and Concluding Analysis
11.2 Potential Market Strategies

Chapter 12 Research Methodology
12.1 Research Process
12.2 Primary Research
12.3 Secondary Research
 

                                                               Global Newborn Screening Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 848.8 Billion

Forecast Period 2024-32 CAGR:

 7.56%

Market Size in 2032:

USD 1635.6 Billion

Segments Covered:

By Test Type
  • Dried Blood Spot Test
  • Hearing Screen Test
  • Critical Congenital Heart Diseases (CCHD) Test

By Product Type
  • Instruments
  • Reagents
  • Assay Kits

By Technology
  • Tandem Mass Spectrometry
  • Hearing Screen Technology
  • Pulse Oximetry Screening Technology
  • Immunoassays and Enzymatic Assays
  • Electrophoresis
  • DNA-Based Assays

By Disease Type
  • Critical Congenital Heart Diseases
  • Newborn Hearing Loss
  • Sickle Cell Disease
  • Phenylketonuria (PKU)
  • Cystic Fibrosis (CF)
  • Maple Syrup Urine Disease
  • Others

By End User
  • Hospital,
  • Paediatric Clinics,
  • Clinics

By Region
  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:
  • Newborn screening is rising due to genetic diseases and awareness of early detection benefits.

Key Market Restraints:
  • The high cost of modern screening technologies and restricted accessibility in low-income locations can slow market expansion.

Key Opportunities:
  • Genetic testing and digital health solutions offer worldwide newborn screening program expansion prospects.

Companies Covered in the report:
  • PerkinElmer Inc., (U.S), Demant A/S (Denmark), Natus Medical Incorporated (U.S), Bio-Rad Laboratories (U.S), Luminex Corporation (US),  F. Hoffmann-La Roche Ltd., (Switzerland), Thermo Fisher Scientific Inc., (U.S), Bruker (US),  Danaher (US), Medtronic (Ireland), Chromsystems Instruments & Chemicals GmbH (Germany), Trivitron Healthcare (India), Baebies Inc., (U.S), and RECIPE Chemicals + Instruments GmbH (Germany), and Other Active Players.

Frequently Asked Questions :

What would be the forecast period in the Newborn Screening Market research report?
The forecast period in the Newborn Screening Market research report is 2024-2032.
Who are the key players in the Newborn Screening Market?
PerkinElmer Inc., (U.S), Demant A/S (Denmark), Natus Medical Incorporated (U.S), Bio-Rad Laboratories (U.S), Luminex Corporation (US), F. Hoffmann-La Roche Ltd., (Switzerland), Thermo Fisher Scientific Inc., (U.S), Bruker (US), Danaher (US), Medtronic (Ireland), Chromsystems Instruments & Chemicals GmbH (Germany), Trivitron Healthcare (India), Baebies Inc., (U.S), and RECIPE Chemicals + Instruments GmbH (Germany), and Other Active Players.
What are the segments of the Newborn Screening Market?
The Newborn Screening Market is segmented into By Test Type, Product Type, Technology Disease Type, End User and region. By Test Type (Dried Blood Spot Test, Hearing Screen Test, Critical Congenital Heart Diseases (CCHD) Test), Product Type (Instruments, Reagents, Assay Kits), Technology (Tandem Mass Spectrometry, Hearing Screen Technology, Pulse Oximetry Screening Technology, Immunoassays and Enzymatic Assays, Electrophoresis, DNA-Based Assays), Disease Type (Critical Congenital Heart Diseases, Newborn Hearing Loss, Sickle Cell Disease, Phenylketonuria (PKU), Cystic Fibrosis (CF), Maple Syrup Urine Disease, Others), End User (Hospital, Paediatric Clinics, Clinics) . By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Russia, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
What is the Newborn Screening Market?
Newborn screening is a public health program aimed at the early identification of specific genetic, metabolic, hormonal, and functional disorders in newborns shortly after birth. Through a series of simple tests, usually involving a blood sample taken from a heel prick, along with hearing and heart defect screenings, newborn screening can detect conditions that might not be apparent at birth but could lead to severe health issues if left untreated. By identifying these conditions early, newborn screening enables timely intervention, treatment, and management, significantly improving the long-term health outcomes for affected infants and preventing potential disabilities, developmental delays, or life-threatening complications.
How big is the Newborn Screening Market?
Newborn Screening Market Size Was Valued at USD 848.8 Million in 2023 and is Projected to Reach USD 1635.6 Million by 2032, Growing at a CAGR of 7.56% From 2024-2032.